Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: diabetes/obesity therapy - Bayer/CuraGen

Next Previous
X
Search
Drug Profile

Research programme: diabetes/obesity therapy - Bayer/CuraGen

Alternative Names: BAY 76-7171; CT052

Latest Information Update: 17 Apr 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer; CuraGen Corporation
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 17 Apr 2009 No development reported - Preclinical for Diabetes mellitus in USA (PO)
  • 23 Dec 2005 The collaboration agreement between Bayer and CuraGen has been revised
  • 28 Oct 2004 Bayer and CuraGen announced that an orally active, small molecule compound has been advanced into preclinical development for type 2 diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top